ACADIA Pharmaceuticals Inc.
Last updated Jun 17, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
2
Clinical Programs
0
Confidence Coverage
77%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Neurology
- Alzheimer's Disease
Highest priority development: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to ACADIA Pharmaceuticals Inc..
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 77%
Active Signals
1
Investigate Priority
0
Opportunity Score
17
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 17, 2026Score 17ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis
Neurology · Alzheimer's Disease
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Clinical trials for medicines: modifying a clinical trial approvalModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to ACADIA Pharmaceuticals Inc. right now?
- Which regulatory precedents should ACADIA Pharmaceuticals Inc. monitor in Neurology and Alzheimer's Disease?
- How does Pridopidine Phase 3 Trial compare to the nearest competitive programs?
- What signals require immediate investigation for ACADIA Pharmaceuticals Inc.?
- Summarize the strategic implications of recent developments for ACADIA Pharmaceuticals Inc..
- Where is the greatest uncertainty in ACADIA Pharmaceuticals Inc.'s competitive positioning?